La cadena de opciones muestra datos clave de las opciones de acciones de Aclaris Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aclaris Therapeutics..

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

ACLARIS THERAPEUTICS INC

Aclaris Therapeutics

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics Inc

News

ACRS

Aclaris Therapeutics Added To Russell 3000 And Russell 2000 Indexes

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Buy and maintains $16 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

Biotech

Health Care

General

Aclaris Therapeutics Initiates Phase 1a/1b Program For ATI-052, The Company's Investigational Bispecific Anti-TSLP/IL-4R Antibody, The Program Will Consist Of A Phase 1a Single And Multiple Ascending Dose Portion In Healthy Volunteers, Followed By An Expected Phase 1b Proof Of Concept Portion

Aclaris Therapeutics Has Initiated A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial Of Bosakitug (ATI-045) For Moderate-to-severe Atopic Dermatitis, Top Line Results Expected In The Second Half Of 2026

WIIM

Aclaris Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced an $8 price target.

<h3>Gainers</h3>
<ul>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares increased by 237.2% to $2.3 during Wednesday's pre-market session. The market value of their outstanding shares is at $128.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock moved upwards by 18.44% to $0.28. The company's market cap stands at $13.9 million. </li>
<li>Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) shares rose 15.91% to $0.59. The market value of their outstanding shares is at $86.4 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 12.77% to $2.56. The market value of their outstanding shares is at $2.4 million. </li>
<li>Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) stock increased by 9.37% to $12.25. The company's market cap stands at $536.5 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 8.66% to $1.38. The company's market cap stands at $149.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) stock decreased by 30.4% to $1.58 during Wednesday's pre-market session. The company's market cap stands at $27.7 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock fell 16.47% to $0.99. The market value of their outstanding shares is at $3.1 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares fell 13.95% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock fell 11.75% to $2.33. The market value of their outstanding shares is at $1.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 10.86% to $447.17. The market value of their outstanding shares is at $5.8 billion. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock decreased by 7.86% to $3.05. The company's market cap stands at $79.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASBP

IMNN

MAZE

NIVF

REVB

SNTI

SONN

SPRO

VERU

WORX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Ami Fadia initiated coverage on Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) with a Buy rating and announced a price target of $45. Alkermes shares closed at $29.90 on Tuesday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Yi Chen initiated coverage on NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) with a Buy rating and announced a price target of $18. NeuroPace shares closed at $12.66 on Tuesday. <a href="https://www.benzinga.com/quote/NPCE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Martin Fan initiated coverage on Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with an Outperform rating and announced a price target of $8. Aclaris Therapeutics shares closed at $1.27 on Tuesday. <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Mike Harrison initiated coverage on Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Neutral rating and announced a price target of $67. Marvell Tech shares closed at $63.82 on Tuesday. <a href="https://www.benzinga.com/quote/MRVL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Mike Harrison initiated coverage on Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) with a Buy rating and announced a price target of $112. Arista Networks shares closed at $92.49 on Tuesday. <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ANET stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-1024x595.png" alt="" class="wp-image-929704" style="width:603px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28074230/image-356.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ALKS

ANET

MRVL

NPCE

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Wedbush analyst Martin Fan initiates coverage on Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Outperform rating and announces Price Target of $8.

Wedbush Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $8

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Buy and lowers the price target from $20 to $16.

HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $16

Earnings

Earnings Beats

Aclaris Therapeutics Q1 EPS $(0.12), Inline, Sales $1.46M Beat $1.28M Estimate

Aclaris shares are trading higher after the company announced FDA clearance of its IND application for a Phase 1A/1B trial of ATI-052.

- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 -
WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1a/1b clinical trial of ATI-052, a potential best-in-class bispecific anti-TSLP/IL-4R monoclonal antibody.
The randomized, blinded, placebo-controlled, Phase 1a/1b clinical trial will evaluate single and multiple ascending doses of ATI-052 followed by a proof-of-concept portion in an undisclosed indication. The Company expects to initiate the trial in the second quarter of 2025.
 &nbsp;

Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2

Cantor Fitzgerald analyst Prakhar Agrawal reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight

Scotiabank analyst Louise Chen initiates coverage on Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Sector Outperform rating and announces Price Target of $15.

Scotiabank Initiates Coverage On Aclaris Therapeutics with Sector Outperform Rating, Announces Price Target of $15

Guidance

Aclaris Therapeutics Expects Cash Runway Into 2028

Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.24) by 320.83 percent. The company reported quarterly sales of $9.21 million which beat the analyst consensus estimate of $2.11 million by 336.89 percent. This is a 47.58 percent decrease over sales of $17.57 million the same period last year.

Earnings Misses

Aclaris Therapeutics Q4 2024 GAAP EPS $(1.01) Misses $(0.24) Estimate, Sales $9.21M Beat $2.11M Estimate

Aclaris Therapeutics Announced The Availability Of A New Publication Describing The Unique Properties Of Aclaris Therapeutics' ATI-2138, A Novel Investigational Covalent Inhibitor Of Interleukin-2-inducible T Cell Kinase And Janus Kinase 3 In Development For The Treatment Of Autoimmune And Inflammatory Diseases

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded Aclaris Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and a <a href="https://www.benzinga.com/quote/ACRS/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $20</a>. The stock gained after the rerating.
In a press release last month, Aclaris announced that it had entered into an exclusive license agreement with privately held Biosion, Inc. for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R.
Despite recent advances in anti-TSLP and anti-IL4R therapies, there remains a substantial unmet need for more effective and convenient treatment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42631016/taiwan-semiconductor-expands-in-japan-sony-and-denso-among-first-customers" rel="noreferrer noopener">Taiwan Semiconductor Expands in Japan: Sony and Denso Among First Customers</a>
In a completed Phase 2a, single-arm, proof-of-concept trial conducted in the U.S. in 22 patients with moderate-to-severe atopic dermatitis, BSI-045B was observed to have a pharmacodynamic, safety, and efficacy profile that could position it as a potential best-in-class therapy.
BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion&#8217;s regional partner, targeting severe asthma and chronic rhinosinusitis with nasal polyps, accelerating the potential to show proof-of-concept across additional indications.
Selvaraju expects Aclaris to initiate multiple mid-stage clinical studies next year in the U.S. due to potential positive results from the Chinese trials. 
This should pave the way for registration programs in the coming years. From Selvaraju&#8217;s vantage point, BSI-045B could generate billions of dollars in sales across solely the U.S. and European Union markets in only chronic asthma and atopic dermatitis indications.
This candidate could reach the U.S. market in 2029 to treat chronic asthma and in 2030 for treating AD, with potential peak annual sales of roughly $9.8 billion. 
Selvaraju&#8217;s forecasts include pricing in the $30K range in the U.S. and the $10K range in Europe, roughly in line with net pricing for Dupixent (dupilumab), the most commercially successful of the currently-marketed anti-IL-4R monoclonal antibodies with estimated 2024 sales totaling roughly 13 billion euros. 
Selvaraju noted that an earlier-generation monoclonal antibody, the anti-IgE agent Xolair (omalizumab), generated sales approaching $4 billion in 2023. Selvaraju ascribed a 30% probability of approval to BSI-045B in chronic asthma and a 20% probability of approval to this candidate in AD.
Selvaraju projected fourth-quarter revenue of $2.9 million and EPS of $(0.10).
Price Action: ACRS stock is up 8% at $2.94 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42627181/blackberry-growth-hinge-on-iot-secure-communications-despite-valuation-concerns-analyst" target="_blank" rel="noreferrer noopener">BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Upgrades

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded GCM Grosvenor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for PotlatchDeltic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

Press Releases

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

Management

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Comments

Aclaris Therapeutics

Aclaris Therapeutics (ACRS) Opciones

Aclaris Therapeutics (NASDAQ:ACRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL